Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 6/2009

01-12-2009

Anti-Inflammatory Activity of Ghrelin in Human Carotid Artery Cells

Authors: Kevin B. S. Chow, Christopher H. K. Cheng, Helen Wise

Published in: Inflammation | Issue 6/2009

Login to get access

Abstract

Receptors for eicosanoids such as prostaglandin E2, prostacyclin and thromboxane A2, as well as the ghrelin receptor polypeptide (GHS-R1b), can all regulate ghrelin (GHS-R1a) receptor activity, by the process of hetero-oligomerization, when heterologously expressed in human embryonic kidney (HEK 293) cells. To determine if such regulation might occur in inflammatory diseases of the vasculature, we incubated human coronary artery endothelial cells and human coronary artery smooth muscle cells with lipopolysaccharide and determined mRNA expression levels of these proteins using real-time PCR. Acute inflammation increased GHS-R1a mRNA in smooth muscle cells and increased cyclo-oxygenase-2 mRNA in endothelial cells; both these changes were attenuated by pretreatment of cells with ghrelin. Lipopolysaccharide did not affect expression of GHS-R1b or prostanoid receptor mRNA. Therefore, hetero-oligomerization of GHS-R1a with GHS-R1b or prostanoid receptors is unlikely to influence GHS-R1a activity in the vasculature; at least under conditions of acute vascular inflammation.
Literature
1.
Holst, B., and T. W. Schwartz. 2004. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol. Sci. 25:113–117.CrossRefPubMed
2.
Wiley, K. E., and A. P. Davenport. 2002. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br. J. Pharmacol. 136:1146–1152.CrossRefPubMed
3.
Waseem, T., M. Duxbury, H. Ito, S. W. Ashley, and M. K. Robinson. 2008. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery. 143:334–342.CrossRefPubMed
4.
Katugampola, S. D., R. E. Kuc, J. J. Maguire, and A. P. Davenport. 2002. G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin. Sci. 103(Suppl. 48):171S–175S.PubMed
5.
Iantorno, M., H. Chen, J. Kim, M. Tesauro, D. Lauro, C. Cardillo, and M. J. Quon. 2007. Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am. J. Physiol. Endocrinol. Metab. 292:E756–E764.CrossRefPubMed
6.
Xu, X., B. Sook Jhun, C. Hoon Ha, and Z. G. Jin. 2008. Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology. 149:4183–4192.CrossRefPubMed
7.
Leung, P. K., K. B. S. Chow, P. N. Lau, K. M. Chu, C. B. Chan, C. H. K. Cheng, and H. Wise. 2007. The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell Signal. 19:1011–1022.CrossRefPubMed
8.
Chow, K. B. S., P. K. Leung, C. H. K. Cheng, W. T. Cheung, and H. Wise. 2008. The constitutive activity of ghrelin receptors is decreased by co-expression with vasoactive prostanoid receptors when over-expressed in human embryonic kidney 293 cells. Int. J. Biochem. Cell Biol. 40:2627–2637.CrossRefPubMed
9.
Cipollone, F., and M. L. Fazia. 2006. COX-2 and atherosclerosis. J. Cardiovasc. Pharmacol. 47:S26–S36.CrossRefPubMed
10.
Norel, X. 2007. Prostanoid receptors in the human vascular wall. Scientific World Journal. 7:1359–1374.PubMed
11.
Gómez-Hernández, A., J. L. Martín-Ventura, E. Sánchez-Galán, C. Vidal, M. Ortego, L. M. Blanco-Colio, L. Ortega, J. Tuñón, and J. Egido. 2006. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-κB. Atherosclerosis. 187:139–149.CrossRefPubMed
12.
Murata, T., F. Ushikubi, T. Matsuoka, M. Hirata, A. Yamasaki, Y. Sugimoto, A. Ichikawa, Y. Aze, T. Tanaka, N. Yoshida, A. Ueno, S. Oh-Ishi, and S. Narumiya. 1997. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 388:678–682.CrossRefPubMed
13.
Kobayashi, T., Y. Tahara, M. Matsumoto, M. Iguchi, H. Sano, T. Murayama, H. Arai, H. Oida, T. Yurugi-Kobayashi, J. K. Yamashita, H. Katagiri, M. Majima, M. Yokode, T. Kita, and S. Narumiya. 2004. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest. 114:784–794.PubMed
14.
Hung, G. H. Y., R. L. Jones, F. F. Y. Lam, K. M. Chan, H. Hidaka, M. Suzuki, and Y. Sasaki. 2006. Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery. Prostaglandins Leukot. Essent. Fatty Acids. 74:401–415.CrossRefPubMed
15.
Fabre, J.-E., M. Nguyen, K. Athirakul, K. Coggins, J. D. McNeish, S. Austin, L. K. Parise, G. A. Fitzgerald, T. M. Coffman, and B. H. Koller. 2001. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J. Clin. Invest. 107:603–610.CrossRefPubMed
16.
Magder, S., J. Neculcea, V. Neculcea, and R. Sladek. 2006. Lipopolysaccharide and TNF-α produce very similar changes in gene expression in human endothelial cells. J. Vasc. Res. 43:447–461.CrossRefPubMed
17.
Wu, S.-Q., and W. C. Aird. 2005. Thrombin, TNF-α, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells. Am. J. Physiol. 289:H873–H885.
18.
Rozen, S., H. J. Skaletsky 2000. Primer3 on the WWW for general users and for biologist programmers. In Bioinformatics Methods and Protocols: Methods in Molecular Biology, Krawetz S, Misener S, eds. Totowa: Humana Press; 365–386.
19.
Viani, I., A. Vottero, F. Tassi, G. Cremonini, C. Sartori, S. Bernasconi, B. Ferrari, and L. Ghizzoni. 2008. Ghrelin Inhibits steroid biosynthesis by cultured granulosa-lutein cells. J. Clin. Endocrinol. Metab. 93:1476–1481.CrossRefPubMed
20.
Kotelevets, L., N. Foudi, L. Louedec, A. Couvelard, E. Chastre, and X. Norel. 2007. A new mRNA splice variant coding for the human EP3-I receptor isoform. Prostaglandins Leukot. Essent. Fatty Acids. 77:195–201.CrossRefPubMed
21.
Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 25:402–408.CrossRefPubMed
22.
Whelan, J. A., N. B. Russell, and M. A. Whelan. 2003. A method for the absolute quantification of cDNA using real-time PCR. J. Immunol. Methods. 278:261–269.CrossRefPubMed
23.
De Vriese, C., F. Gregoire, P. De Neef, P. Robberecht, and C. Delporte. 2005. Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation. Endocrinology. 146:1514–1522.CrossRefPubMed
24.
Wu, R., M. Zhou, X. Cui, H. H. Simms, and P. Wang. 2004. Upregulation of cardiovascular ghrelin receptor occurs in the hyperdynamic phase of sepsis. Am. J. Physiol. 287:H1296–H1302.CrossRef
25.
Li, A., G. Cheng, G. H. Zhu, and A. S. Tarnawski. 2007. Ghrelin stimulates angiogenesis in human microvascular endothelial cells: implications beyond GH release. Biochem. Biophys. Res. Commun. 353:238–243.CrossRefPubMed
26.
Gnanapavan, S., B. Kola, S. A. Bustin, D. G. Morris, P. McGee, P. Fairclough, S. Bhattacharya, R. Carpenter, A. B. Grossman, and M. Korbonits. 2002. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 87:2988–2991.CrossRefPubMed
27.
Barzon, L., M. Pacenti, G. Masi, A. L. Stefani, K. Fincati, and G. Palù. 2005. Loss of growth hormone secretagogue receptor 1a and overexpression of type 1b receptor transcripts in human adrenocortical tumors. Oncology. 68:414–421.CrossRefPubMed
28.
Luque, R. M., R. D. Kineman, S. Park, X. D. Peng, F. Gracia-Navarro, J. P. Castano, and M. M. Malagon. 2004. Homologous and heterologous regulation of pituitary receptors for ghrelin and growth hormone-releasing hormone. Endocrinology. 145:3182–3189.CrossRefPubMed
29.
Yeung, C. M., C. B. Chan, and C. H. K. Cheng. 2004. Isolation and characterization of the 5′-flanking region of the growth hormone secretagogue receptor gene from black seabream Acanthopagrus schlegeli. Mol. Cell. Endocrinol. 223:5–15.CrossRefPubMed
30.
Barreiro, M. L., L. Pinilla, E. Aguilar, and M. Tena-Sempere. 2002. Expression and homologous regulation of GH secretagogue receptor mRNA in rat adrenal gland. Eur. J. Endocrinol. 147:677–688.CrossRefPubMed
31.
Holst, B., N. D. Holliday, A. Bach, C. E. Elling, H. M. Cox, and T. W. Schwartz. 2004. Common structural basis for constitutive activity of the ghrelin receptor family. J. Biol. Chem. 279:53806–53817.CrossRefPubMed
32.
Mousseaux, D., L. Le Gallic, J. Ryan, C. Oiry, D. Gagne, J. A. Fehrentz, J. C. Galleyrand, and J. Martinez. 2006. Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCε pathway. Br. J. Pharmacol. 148:350–365.CrossRefPubMed
33.
Rossi, F., A. Castelli, M. J. Bianco, C. Bertone, M. Brama, and V. Santiemma. 2008. Ghrelin induces proliferation in human aortic endothelial cells via ERK1/2 and PI3K/Akt activation. Peptides. 29:2046–2051.CrossRefPubMed
34.
Rossi, F., A. Castelli, M. J. Bianco, C. Bertone, M. Brama, and V. Santiemma. 2009. Ghrelin inhibits contraction and proliferation of human aortic smooth muscle cells by cAMP/PKA pathway activation. Atherosclerosis. 203:97–104.CrossRefPubMed
35.
Cao, J. M., H. Ong, and C. Chen. 2006. Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends Endocrinol. Metab. 17:13–18.CrossRefPubMed
36.
Tan, X., S. Essengue, J. Talreja, J. Reese, D. J. Stechschulte, and K. N. Dileepan. 2007. Histamine directly and synergistically with lipopolysaccharide stimulates cyclooxygenase-2 expression and prostaglandin I2 and E2 production in human coronary artery endothelial cells. J. Immunol. 179:7899–7906.PubMed
Metadata
Title
Anti-Inflammatory Activity of Ghrelin in Human Carotid Artery Cells
Authors
Kevin B. S. Chow
Christopher H. K. Cheng
Helen Wise
Publication date
01-12-2009
Publisher
Springer US
Published in
Inflammation / Issue 6/2009
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-009-9149-8

Other articles of this Issue 6/2009

Inflammation 6/2009 Go to the issue

OriginalPaper

Decreased Proinflammatory Cytokines Production in Children with Complicated Parapneumonic Pleural Effusion after Intrapleural Fibrinolytic Treatment

OriginalPaper

Anti-inflammatory and Immunomodulatory Effects of Baccharis trimera Aqueous Extract on Induced Pleurisy in Rats and Lymphoproliferation In Vitro

OriginalPaper

Activation of PPAR-γ by Carbon Monoxide from CORM-2 Leads to the Inhibition of iNOS but not COX-2 Expression in LPS-Stimulated Macrophages

OriginalPaper

Procaterol Inhibits Lung Fibroblast Migration

OriginalPaper

Experimental Periodontitis Induces a cAMP-dependent Increase in Amylase Activity in Parotid Glands from Male Rats

OriginalPaper

Association of Ang-2 with Integrin β2 Controls Ang-2/PDGF-BB-Dependent Upregulation of Human Peripheral Blood Monocyte Fibrinolysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits